Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bens, Annet ; Dehlendorff, Christian ; Friis, Søren ; Cronin-Fenton, Deirdre ; Jensen, Maj-Britt ; Ejlertsen, Bent ; Lash, Timothy L ; Kroman, Niels ; Mellemkjær, Lene. / The role of H1 antihistamines in contralateral breast cancer : a Danish nationwide cohort study. In: British Journal of Cancer. 2020 ; Vol. 122, No. 7. pp. 1102-1108.

Bibtex

@article{de342f8ff17c4874b77ee6c4cd3f1b11,
title = "The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study",
abstract = "BACKGROUND: Preclinical studies have shown both pro- and antineoplastic effects of antihistamines. Here, we evaluated the effect of H1 antihistamines on contralateral breast cancer (CBC) risk, and whether cationic amphiphilic (CAD) antihistamines could increase the sensitivity to chemotherapy.METHODS: From the Danish Breast Cancer Group clinical database, we identified all women aged ≥20 years with a first-time diagnosis of breast cancer during 1996-2012. Information on drug use, CBC and potential confounding factors was retrieved from nationwide registries. Using Cox proportional hazard regression models, we calculated hazard ratios (HRs) and 95{\%} confidence intervals (CIs) for CBC associated with H1-antihistamine use.RESULTS: We identified 52,723 patients with breast cancer with a total of 310,583 person-years of follow-up. Among them, 1444 patients developed a new primary tumour in the contralateral breast. Post-diagnosis use of H1 antihistamines (≥2 prescriptions) was not strongly associated with CBC risk (HR 1.08, 95{\%} CI: 0.90-1.31) compared with non-use (<2 prescriptions). Use of CAD antihistamines among patients receiving chemotherapy was not associated with a decrease in CBC risk.CONCLUSIONS: Taken together, our findings do not suggest any association of H1-antihistamine use with CBC development.",
author = "Annet Bens and Christian Dehlendorff and S{\o}ren Friis and Deirdre Cronin-Fenton and Maj-Britt Jensen and Bent Ejlertsen and Lash, {Timothy L} and Niels Kroman and Lene Mellemkj{\ae}r",
year = "2020",
month = "3",
doi = "10.1038/s41416-020-0747-4",
language = "English",
volume = "122",
pages = "1102--1108",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

RIS

TY - JOUR

T1 - The role of H1 antihistamines in contralateral breast cancer

T2 - a Danish nationwide cohort study

AU - Bens, Annet

AU - Dehlendorff, Christian

AU - Friis, Søren

AU - Cronin-Fenton, Deirdre

AU - Jensen, Maj-Britt

AU - Ejlertsen, Bent

AU - Lash, Timothy L

AU - Kroman, Niels

AU - Mellemkjær, Lene

PY - 2020/3

Y1 - 2020/3

N2 - BACKGROUND: Preclinical studies have shown both pro- and antineoplastic effects of antihistamines. Here, we evaluated the effect of H1 antihistamines on contralateral breast cancer (CBC) risk, and whether cationic amphiphilic (CAD) antihistamines could increase the sensitivity to chemotherapy.METHODS: From the Danish Breast Cancer Group clinical database, we identified all women aged ≥20 years with a first-time diagnosis of breast cancer during 1996-2012. Information on drug use, CBC and potential confounding factors was retrieved from nationwide registries. Using Cox proportional hazard regression models, we calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with H1-antihistamine use.RESULTS: We identified 52,723 patients with breast cancer with a total of 310,583 person-years of follow-up. Among them, 1444 patients developed a new primary tumour in the contralateral breast. Post-diagnosis use of H1 antihistamines (≥2 prescriptions) was not strongly associated with CBC risk (HR 1.08, 95% CI: 0.90-1.31) compared with non-use (<2 prescriptions). Use of CAD antihistamines among patients receiving chemotherapy was not associated with a decrease in CBC risk.CONCLUSIONS: Taken together, our findings do not suggest any association of H1-antihistamine use with CBC development.

AB - BACKGROUND: Preclinical studies have shown both pro- and antineoplastic effects of antihistamines. Here, we evaluated the effect of H1 antihistamines on contralateral breast cancer (CBC) risk, and whether cationic amphiphilic (CAD) antihistamines could increase the sensitivity to chemotherapy.METHODS: From the Danish Breast Cancer Group clinical database, we identified all women aged ≥20 years with a first-time diagnosis of breast cancer during 1996-2012. Information on drug use, CBC and potential confounding factors was retrieved from nationwide registries. Using Cox proportional hazard regression models, we calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with H1-antihistamine use.RESULTS: We identified 52,723 patients with breast cancer with a total of 310,583 person-years of follow-up. Among them, 1444 patients developed a new primary tumour in the contralateral breast. Post-diagnosis use of H1 antihistamines (≥2 prescriptions) was not strongly associated with CBC risk (HR 1.08, 95% CI: 0.90-1.31) compared with non-use (<2 prescriptions). Use of CAD antihistamines among patients receiving chemotherapy was not associated with a decrease in CBC risk.CONCLUSIONS: Taken together, our findings do not suggest any association of H1-antihistamine use with CBC development.

U2 - 10.1038/s41416-020-0747-4

DO - 10.1038/s41416-020-0747-4

M3 - Journal article

VL - 122

SP - 1102

EP - 1108

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -

ID: 60076739